文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

重度细胞因子释放综合征与CD19 CAR-T治疗后血液学毒性相关

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy.
PubMed 文献 · Blood Adv · 2022-01-01

该研究回顾性分析173例接受CD19 CAR-T治疗的复发/难治B细胞恶性肿瘤患者,主要终点为输注后28天中性粒细胞和血小板计数。结果显示28天中性粒细胞和血小板恢复累积发生率分别为81%和75%,CRS严重程度升高是血小板计数降低的独立预测因素,而淋巴清除前血小板计数较低则独立预测中性粒细胞和血小板计数降低。

要点

  • CD19 CAR-T后28天中性粒细胞和血小板恢复累积发生率分别为81%和75%。
  • CRS严重程度升高独立预测血小板计数降低。
  • 淋巴清除前血小板计数较低独立预测中性粒细胞和血小板计数降低。

核心结论

  • 重度CRS与CD19 CAR-T治疗后血小板计数降低独立相关。
  • 淋巴清除前血小板计数较低独立预测中性粒细胞和血小板计数降低。

研究设计与样本

  • 回顾性分析173例在1/2期临床试验(NCT01865617)中接受固定成分CD19 CAR-T治疗的患者。
  • 主要终点为CAR-T输注后28天绝对中性粒细胞计数和血小板计数。

主要发现

  • 28天中性粒细胞恢复累积发生率为81%,血小板恢复累积发生率为75%。
  • 末次随访时持续中性粒细胞减少发生率为9%,持续血小板减少发生率为14%。
  • 使用debias LASSO回归分析,CRS严重程度升高是血小板计数降低的独立预测因素。
  • 淋巴清除前血小板计数较低是中中性粒细胞和血小板计数降低的独立预测因素。
  • 多变量模型显示IL-6峰值血清浓度较高与28天细胞计数较低相关,TGF-β1血清浓度较高与细胞计数较高相关。

临床怎么用

  • 患者选择和改善CRS管理可能促进CD19 CAR-T治疗后的造血恢复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in patients with relapsed/refractory B-cell malignancies; however, it is associated with toxicities including cytokine release syndrome (CRS), neurotoxicity, and impaired hematopoietic recovery. The latter is associated with high-grade cytopenias requiring extended growth factor or transfusional support, potentially leading to additional complications such as infection or hemorrhage. To date, the factors independently associated with hematologic toxicity have not been well characterized. To address this deficit, we retrospectively analyzed 173 patients who received defined-composition CD19 CAR T-cell therapy in a phase 1/2 clinical trial (https://clinicaltrials.gov; NCT01865617), with primary end points of absolute neutrophil count and platelet count at day-28 after CAR T-cell infusion. We observed cumulative incidences of neutrophil and platelet recovery of 81% and 75%, respectively, at 28 days after infusion. Hematologic toxicity was noted in a significant subset of patients, with persistent neutropenia in 9% and thrombocytopenia in 14% at last follow-up. Using debiased least absolute shrinkage selector and operator regression analysis for high-dimensional modeling and considering patient-, disease-, and treatment-related variables, we identified increased CRS severity as an independent predictor for decreased platelet count and lower prelymphodepletion platelet count as an independent predictor of both decreased neutrophil and platelet counts after CD19 CAR T-cell infusion. Furthermore, multivariable models including CRS-related cytokines identified associations between higher peak serum concentrations of interleukin-6 and lower day-28 cell counts; in contrast, higher serum concentrations of transforming growth factor-β1 were associated with higher counts. Our findings suggest that patient selection and improved CRS management may improve hematopoietic recovery after CD19 CAR T-cell therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Juluri KR, Wu QV, Voutsinas J, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2022. PMID: 34666344. doi:10.1182/bloodadvances.2020004142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。